ClinicalTrials.gg
CompletedNCT06431438Updated May 28, 2024

Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of TQA3810 Tablets

A Phase 1 interventional study of TQA3810 in Chronic Hepatitis B, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-28.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Oct 2021, registered May 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
759
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited — 4 open to participants now, 6 under way, 1 of them phase 3. Hepatitis B, Chronic · Sino Biopharmaceutical Limited.

Enrollment
2nd of 13
759 · median 116
Started
2021
the only one that year
Phase 1
2 of 13
1 open now
Registered
8th of 13
by date

Among the 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited, this one is the 2nd largest by enrollment, is the only one that started in 2021, is one of 2 in phase 1, and was the 8th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

4 of the 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

This study was a single-center study, including randomized, double-blind, placebo-controlled, single-dose escalation study, multiple-dose study, food effect on pharmacokinetics and drug metabolism transformation study, drug interaction study. To evaluate the tolerability, pharmacokinetics and metabolic transformation of TQA3810 in healthy subjects after single or multiple doses of TQA3810, the drug-drug interactions between TQA3810 tablets and entecavir dispersible tablets, and the pharmacokinetic properties of TQA3810 tablets in combination.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign the before the trial, and fully understand the trial content, process and possible adverse reactions;
  • Able to complete the study according to the requirements of the trial protocol;
  • The participants (including their partners) are willing to voluntarily use effective methods within 6 months from screening until the last dose of study drug, as detailed in the Appendix;
  • Male and female subjects aged 18-55 years old (including 18 and 55 years old);
  • The body weight of male subjects should not be less than 50 kg and the body weight of female subjects should not be less than 45 kg. (BMI) = weight (kg)/height 2 (m2), BMI in the range of 18-28 kg/m2 (including the cut-off value);
  • The physical examination and vital signs were normal or abnormal without clinical significance.

Exclusion criteria

Exclusion Criteria:

  • Smoking more than 5 cigarettes per day in the 3 months before the study;
  • Allergic constitution (multi-drug and food allergy);
  • A history of drug and/or alcohol abuse (drinking 14 units of alcohol per week: 1 unit = 285 mL beer, or 25 mL spirits, or 100 ml wine);
  • Donation or massive blood loss (> 400 mL) within 3 months before screening;
  • Taking any drugs that alter liver enzyme activity 28 days before screening;
  • Have taken any prescription medication, over-the-counter medication, any vitamin product or herbal medicine within 14 days before screening;
  • Those who had taken special diet (including dragon fruit, mango, grapefruit, etc.) or had strenuous exercise within 2 weeks before screening, or had other factors affecting drug absorption, distribution, metabolism, and excretion;
  • Combined with the following inhibitors or inducers of , P-gp, or Bcrp, such as itraconazole, ketoconazole, or dronedarone, within three months before taking the study drug;
  • A recent major change in diet or exercise habits;
  • Have taken a study drug or participated in a clinical trial of the drug within three months before taking the study drug;
  • A history of dysphagia or any gastrointestinal disorder affecting drug absorption or a history of cholecystectomy or biliary tract disease;
  • Have any condition that increases the risk of bleeding, such as hemorrhoids, acute gastritis or gastric and duodenal ulcers;
  • With severe systemic diseases and related medical history (including subjects with active or occult tuberculosis, a history of tuberculosis, or clinical manifestations suspected of tuberculosis), as well as immune system diseases and medical history;
  • Had systemic or local infection within 2 months prior to screening, and were hospitalized for severe infection and/or required intravenous antibiotics;
  • Subjects who were unable to tolerate a standard meal;
  • An (ECG) abnormalities have clinical significance;
  • The female subjects were lactating or seropositive for pregnancy during the screening or test period;
  • abnormalities on clinical examination or other clinical findings within 6 months prior to screening (including but not limited to gastrointestinal, renal, hepatic, neurological, hematologic, endocrine, oncologic, pulmonary, immune, psychiatric, or cardio-cerebrovascular diseases);
  • Clinically significant fundus lesions (symptomatic cotton-like fundus changes) and retinopathy;
  • Viral hepatitis (including and C), AIDS antibody, treponema pallidum antibody positive;
  • From the screening stage to the onset of acute illness or concomitant medication before study medication;
  • Consumption of chocolate, any caffeinated or xanthine-rich food or beverage 24 hours before taking the study drug;
  • Have taken any alcohol-based product within 24 hours before taking the study medication;
  • Having a positive urine drug screen or having a history of drug abuse or drug use in the past 5 years;
  • Subjects with other factors considered by the investigator to be ineligible for the trial.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
759 participants (actual)

Study arms

  • Placebo comparator
    0.5mg single-dose

    Ten subjects were enrolled, of whom 8 received the trial drug and 2 received placebo.

    Drug: TQA3810

  • Placebo comparator
    1.0mg single-dose

    Ten subjects were enrolled, of whom 8 received the trial drug and 2 received placebo.

    Drug: TQA3810

  • Other
    Food impact group

    Sixteen subjects were enrolled and all received the trial drug.

    Drug: TQA3810

  • Placebo comparator
    0.1mg single-dose

    Ten subjects were enrolled, of whom 8 received the trial drug and 2 received placebo.

    Drug: TQA3810

  • Placebo comparator
    0.3mg single-dose

    Ten subjects were enrolled, of whom 8 received the trial drug and 2 received placebo.

    Drug: TQA3810

  • Active comparator
    Drug interaction group

    Sixteen subjects were enrolled and all received the trial drug.

    Drug: TQA3810

  • Placebo comparator
    0.1mg multiple dosing

    Ten subjects were enrolled, of whom 8 received the trial drug and 2 received placebo.

    Drug: TQA3810

  • Placebo comparator
    0.3mg multiple dosing

    Ten subjects were enrolled, of whom 8 received the trial drug and 2 received placebo.

    Drug: TQA3810

  • Placebo comparator
    0.5mg multiple dosing

    Ten subjects were enrolled, of whom 8 received the trial drug and 2 received placebo.

    Drug: TQA3810

  • Placebo comparator
    0.2mg multiple dosing

    Ten subjects were enrolled, of whom 8 received the trial drug and 2 received placebo.

    Drug: TQA3810

Interventions

  • DrugTQA3810

    TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events

    Occurrence of all adverse events (AEs), serious adverse events (SAEs), and treatment-related adverse events (TEAEs) were recorded.

    Time frame: From the subject signed the informed consent form to 30 days after the last dose

Secondary outcomes

  1. Cmax

    Maximum plasma drug concentration

    Time frame: Single dose escalation study: within 60 minutes pre-dose of day 1; 5, 10, 20, 30, 45 minutes, 1, 1.5, 2, 2.5, 3, 4, 5, 7, and 12 hours post-dose

  2. Tmax

    To maximum plasma drug concentration time.

    Time frame: Single dose escalation study: within 60 minutes pre-dose of day 1; 5, 10, 20, 30, 45 minutes, 1, 1.5, 2, 2.5, 3, 4, 5, 7, and 12 hours post-dose

  3. Half-life (t1/2)

    Drug half-life in plasma.

    Time frame: Single dose escalation study: within 60 minutes pre-dose of day 1; 5, 10, 20, 30, 45 minutes, 1, 1.5, 2, 2.5, 3, 4, 5, 7, and 12 hours post-dose

  4. AUC0-t

    Plasma drug concentration from time 0 to the last measurable area under the drug concentration time curve.

    Time frame: Single dose escalation study: within 60 minutes pre-dose of day 1; 5, 10, 20, 30, 45 minutes, 1, 1.5, 2, 2.5, 3, 4, 5, 7, and 12 hours post-dose

  5. AUC0-∞

    Area under the plasma drug concentration time curve from time 0 to infinity.

    Time frame: Single dose escalation study: within 60 minutes pre-dose of day 1; 5, 10, 20, 30, 45 minutes, 1, 1.5, 2, 2.5, 3, 4, 5, 7, and 12 hours post-dose

07

Study locations

1 site
  • Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University
    Nanjing, Jiangsu 210008, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Nov 2023, 25 months.

Of 73 industry-sponsored phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 25 months is above that.

Counting every sponsor, half of 81 studies reached it within 16 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2024
First posted
May 28, 2024
StartActual
Oct 1, 2021
Primary completionActual
Nov 20, 2023
CompletionActual
Nov 20, 2023
Last update
May 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06431438
Responsible party
Sponsor
First posted
May 28, 2024
Start date
Oct 1, 2021
Primary completion
Nov 20, 2023
Completion
Nov 20, 2023
Last update
May 28, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion